PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.73%
EBIT growth similar to TRAW's 10.07%. Walter Schloss might infer both firms share similar operational efficiencies.
2.45%
Operating income growth under 50% of TRAW's 10.27%. Michael Burry would be concerned about deeper cost or sales issues.
10.71%
Net income growth comparable to TRAW's 10.12%. Walter Schloss might see both following similar market or cost trajectories.
23.59%
EPS growth above 1.5x TRAW's 10.14%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
23.59%
Diluted EPS growth above 1.5x TRAW's 10.14%. David Dodd would see if there's a robust moat protecting these shareholder gains.
16.70%
Share count expansion well above TRAW's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
16.70%
Diluted share count expanding well above TRAW's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-19.06%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-18.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42182.97%
Negative 10Y OCF/share CAGR while TRAW stands at 63.35%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-53680.51%
Negative 5Y OCF/share CAGR while TRAW is at 63.35%. Joel Greenblatt would question the firm’s operational model or cost structure.
-38238.10%
Negative 3Y OCF/share CAGR while TRAW stands at 63.35%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-21634.42%
Negative 10Y net income/share CAGR while TRAW is at 7.24%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-19064.37%
Negative 5Y net income/share CAGR while TRAW is 7.24%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-68658.62%
Negative 3Y CAGR while TRAW is 7.24%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-3403.93%
Negative equity/share CAGR over 10 years while TRAW stands at 110.23%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-569.70%
Negative 5Y equity/share growth while TRAW is at 110.23%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-664.70%
Negative 3Y equity/share growth while TRAW is at 110.23%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-169.45%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
6.82%
We increase R&D while TRAW cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-13.19%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.